GlassScriptPhysician profile
James D Lord
NPI 1780799759
$19,234.27
in general payments reported to CMS, 2019-2025
10 companies · $5,446 in 2025
The $5,446 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,030 · 2021: $3,480 · 2022: $73.65 · 2023: $1,205 · 2025: $5,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,345 · Food and Beverage: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,345.00 |
| Food and Beverage | $305.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,667.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,743.76 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $2,560.00 | 2025 | |
| Janssen Biotech, INC. | $2,250.00 | 2025 | Tremfya |
| Vertex Pharmaceuticals Incorporated | $1,685.00 | 2023-2025 | |
| Abbvie INC. | $135.80 | 2025 | |
| Pfizer INC. | $118.35 | 2019 | |
| Celgene Corporation | $60.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.04 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.